Management Team

NKMAX

NKMAX is headquartered in South Korea and was founded in 2002. The company's biological research reagents are currently solely distributed by headquarters in South Korea. An executive staff including CEO, Sangwoo Park, leads NKMAX and its divisions in Canada and the United States.

 

 

Sangwoo Park
Chief Executive Officer

Yonghwan Cho
Executive Managing Director

Pierre Gagnon
International Marketing Director

Jongsun Kim, Ph.D.
Nonexecutive Director

Jaemyun Lee, M.D.
Nonexecutive Director

Paul Y. Song, M.D.
Chief Medical Officer of NKMAX America
and Expert Advisor of NKMAX


NKMAX Canada

NKMAX Canada Inc. a wholly owned subsidiary of NKMAX, is an immunodiagnostic company focused on the development of in vitro diagnostic devices for the analysis of patients’ immune function. Immunosurveillance performed by lymphoid cells is important in immunity against foreign antigens and tumor cells. NKMAX Canada is a federal corporation that was formed in May 2013. It started operations in September 2013, and its principal mandate has been to introduce NKMAX’s NK cell activity diagnostic test to the Canadian market and confirm its clinical utility based on the South Korean data.

 

 

Sangwoo Park
Chief Executive Officer

Dr. Katia Betito, Ph.D.
President

Dr. Roberto Rodriguez-Suarez, Ph.D.
Medical Science Liaison
and Technical Expert


NKMAX America

NKMAX America, a Delaware wholly owned C-corporation by NKMAX, was formed in March 2014 to expand NKMAX’s diagnostic market to the USA. It has made NKMAX’s NK cell activity test available as a laboratory developed test with the cooperation of Cynvenio, a cancer diagnostic company focused on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood.

 

 

Sangwoo Park
Chief Executive Officer

Paul Y. Song, M.D.
Chief Medical Officer
and Expert Advisor of NKMAX

 

 

 

0